---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-006528"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2023-09-19T23:59:59+00:00"
generated_at: "2026-06-10T13:36:44.215404+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# CNS Pharma shareholders approve director slate, auditor, and 2020 equity plan amendment

## Summary
- All 7 director nominees elected with majority votes; broker non-votes of 1.4M shares.
- Ratified MaloneBailey LLP as independent auditor for FY2023 (1.7M for, 40k against).
- Approved amendment to 2020 Equity Plan, increasing shares by 745,800 to total 845,800.
- Equity plan amendment also modified annual award limits per Participant.
- Director election and equity plan amendments each had 1.4M broker non-votes.

## SEC filing metadata
- accession: 0001683168-23-006528
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2023-09-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316823006528/0001683168-23-006528-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316823006528/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-006528
- JSON: https://secwatch.observer/filing/0001683168-23-006528.json
- Plain text: https://secwatch.observer/filing/0001683168-23-006528.txt

## Key facts
- Shareholder Votes
  CNS Pharmaceuticals, Inc. shareholders approved To approve amendments to the Company’s 2020 Stock Plan including an increase in the number of shares of common stock authorized for issuance under the 2020 Plan at the 2023-09-14 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-09-14
  source text: Proposal 3. To approve amendments to the Company’s 2020 Stock Plan (the “2020 Plan”) including an increase in the number of shares of common stock authorized for issuance under the 2020 Plan – The Company’s stockholders approved an amendment to the 2020 Plan to increase the number of shares of common stock authorized for issuance under the 2020 Plan by 745,800 shares and to modify the maximum annual limits on awards issuable under the 2020 Plan, by the following vote:
  evidence_url: https://www.sec.gov/Archives/edgar/data/1729427/000168316823006528/0001683168-23-006528-index.htm
- Shareholder Votes
  CNS Pharmaceuticals, Inc. shareholders approved Election of Directors at the 2023-09-14 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-09-14
  source text: Proposal 1. Election of Directors - The Company’s stockholders elected John Climaco, Jerzy (George) Gumulka, Jeffry R. Keyes, Andrzej Andraczke, Carl Evans, Faith Charles and Bettina Cockroft to serve until the 2024 Annual Meeting of Stockholders, or until their successors are duly elected and qualified, by the following vote.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1729427/000168316823006528/0001683168-23-006528-index.htm
- Shareholder Votes
  CNS Pharmaceuticals, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-09-14 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-09-14
  source text: Proposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm - The Company's stockholders ratified the appointment of MaloneBailey, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023, by the following vote:
  evidence_url: https://www.sec.gov/Archives/edgar/data/1729427/000168316823006528/0001683168-23-006528-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.